The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023

Tuesday, February 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 11, 2019 /PRNewswire/ -- About this marketConjunctivitis is inflammation in the inside of the eyelids

and the covering of the white of the eye, which causes the conjunctival blood vessels to dilate. While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate. The
ease of availability of antibiotic eye drops and ointments for the treatment of bacterial conjunctivitis and antibiotics for viral conjunctivitis is leading to an increase in the use of these therapeutics. The use of therapeutics is primarily to avoid the progression of the disease into severe indications, which could increase the economic burden of patients. Hence, the infectious nature of the disease is expected to increase the adoption rate of therapeutics, thus resulting in the growth of the market during the forecast period. Technavio's analysts have predicted that the conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.Read the full report: https://www.reportlinker.com/p05734247 Market OverviewGrowing allergy casesAllergic conjunctivitis is caused by various types of allergies such as hay fever and asthma. Being allergic to substances such as dust mites and mold can also increase the risk of infection. Globally. the prevalence of various types of allergies has been growing at a significant rate. The increasing prevalence of allergies such as dust mite allergy and pollen allergy increase the risk of allergic conjunctivitis.Patent cliffOne of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market. Patent expiration leads to the increasing launch of generic drugs, thereby leading to value erosion of the global market. The patent expiry of blockbuster drugs also impacts the sales of the vendors significantly, making it difficult for vendors to compete in the market. Thus, the patent expiry of blockbuster drugs and the subsequent entry of generics restrict market growth.For the detailed list of factors that will drive and challenge the growth of the conjunctivitis therapeutics market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Read the full report: https://www.reportlinker.com/p05734247 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-conjunctivitis-therapeutics-market-will-register-a-cagr-of-over-8-by-2023-300793243.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store